BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Livdelzi (Seladelpar) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Livdelzi (Seladelpar)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07305363-1117@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Livdelzi (Seladelpar): Phase 2 readout est. (NCT07305363)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 2.\nStudy: Seladelpar in Adult Li
 ver Transplant Recipients With Ischemic Cholangiopathy (SELIC).\nEstimated
  primary completion: September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/seladelpar#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07305363
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03301506-1117@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT03301506)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar in Participants With Primary Biliary Cholangit
 is (PBC)\nEstimated primary completion: November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03301506
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841977-1117@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Livdelzi (Seladelpar): Phase 2 readout est. (NCT07841977)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 2\, Primary Biliary Cholangitis.\
 nStudy: Study of Seladelpar and Cilofexor in Participants With Primary Bil
 iary Cholangitis\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07841977
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051617-1117@assetmemo.bio
DTSTAMP:20261121T004040Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Livdelzi (Seladelpar): Phase 3 readout est. (NCT06051617)
DESCRIPTION:Livdelzi (Seladelpar)\, phase 3\, Primary Biliary Cholangitis.\
 nStudy: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and 
 Compensated Cirrhosis\nEstimated primary completion: August 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/seladelpar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06051617
URL:https://assetmemo.bio/drug/seladelpar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
